Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Wegovy, like Zepbound, is FDA-approved for weight loss. Its main ingredient is semaglutide, which is also found in Ozempic, a medication that is approved by the FDA to treat Type 2 diabetes but is ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...

The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity.

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billion Danish kroner). Access and affordability have limited wider use of the drugs.